Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Thursday, Feb 13, 2025 4:32 pm ET
4min read Heron Therapeutics (HRTX) is set to release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The company will host a conference call and live webcast at 8:00 a.m. ET to discuss its financial performance and recent business highlights. Investors and analysts are eagerly awaiting the results, as they will provide valuable insights into the company's progress and future prospects.
Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing best-in-class therapies for acute care and oncology patients. The company's product pipeline includes SUSTOL® for chemotherapy-induced nausea and vomiting prevention (CINV), CINVANTI® for CINV, ZYNRELEF® for postoperative pain management, and APONVIE™ for postoperative nausea and vomiting (PONV). These products have shown promising results in clinical trials and have the potential to significantly impact the lives of patients.
HRTX
Indication | Company Introduction |
|---|---|
| Post operative acute pain | Heron Therapeutics, Inc. The company was founded in February 1983 in California as AMCO Polymerics Corporation (AMCO). AMCO changed its name to Advanced Polymer Systems in 1984 and was re-incorporated in Delaware in 1987. The company, which changed its name to AP Pharma in May 2001 to reflect its new pharmaceutical focus, is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve healthcare. The company's main focus is on its leading product candidate, APF 530, which was developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The company's core Biochronomer technology includes biocorrosive polymers designed to release drugs within a specified period of time, and its APF 530 and other product candidates are developed based on this technology. The company has completed more than 100 in vivo and in vitro studies, and the results show that the company's Biochronomer technology may be applicable to a variety of therapeutic areas, including prevention of nausea and vomiting, pain management, inflammation control and ophthalmic disease treatment. The company also completed comprehensive animal and human toxicology studies and concluded that its Biochronomer polymer is safe and well tolerated. In addition, the company's Biochronomer technology can be used to release drugs within days or months. |
| Post operative acute pain | Heron Therapeutics, Inc. The company was founded in February 1983 in California as AMCO Polymerics Corporation (AMCO). AMCO changed its name to Advanced Polymer Systems in 1984 and was re-incorporated in Delaware in 1987. The company, which changed its name to AP Pharma in May 2001 to reflect its new pharmaceutical focus, is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve healthcare. The company's main focus is on its leading product candidate, APF 530, which was developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The company's core Biochronomer technology includes biocorrosive polymers designed to release drugs within a specified period of time, and its APF 530 and other product candidates are developed based on this technology. The company has completed more than 100 in vivo and in vitro studies, and the results show that the company's Biochronomer technology may be applicable to a variety of therapeutic areas, including prevention of nausea and vomiting, pain management, inflammation control and ophthalmic disease treatment. The company also completed comprehensive animal and human toxicology studies and concluded that its Biochronomer polymer is safe and well tolerated. In addition, the company's Biochronomer technology can be used to release drugs within days or months. |
Name |
|---|
| Heron TherapeuticsHRTX |
| Heron TherapeuticsHRTX |
Analysts have a consensus "Buy" rating for Heron Therapeutics, with an average twelve-month price prediction of $7.00, a high estimate of $10.00, and a low estimate of $4.00. This suggests a significant potential upside from the stock’s closing price of $1.79 on December 22, 2023. The company's earnings are expected to improve in the coming year, moving from a loss of ($0.90) per share to a projected loss of ($0.40) per share. This improvement in earnings is a positive sign that may underpin the analysts' optimistic stock price targets for the company.
Heron Therapeutics has made notable progress with its product offerings, particularly with drugs such as Aponvie and Zynrelef. The company's earnings call presentation for Q3'23 highlighted the net sales of these products, suggesting a trajectory towards profitability. Furthermore, the company has a Prescription Drug User Fee Act (PDUFA) goal date of January 23, 2024, which provides a near-term catalyst that could potentially boost the company’s stock performance.
Institutional and retail investors hold a mix of Heron Therapeutics' stock, providing stability to the stock price. The company's diverse ownership base includes institutional investors with long-term investment horizons and significant research capabilities. This diverse ownership structure can help drive demand for the stock and contribute to its growth.
As Heron Therapeutics prepares to report its fourth quarter and full year 2024 financial results, investors and analysts will be closely monitoring the company's progress, particularly in relation to its PDUFA goal date and the subsequent performance of its key products in the market. With cautious optimism, Heron Therapeutics may indeed prove to be a compelling buy into 2024, provided it continues to execute its business strategy effectively and navigate the complex regulatory landscape successfully.
To become a better investor with our AI Assistant @ kavout.com/investgpt
